Tumor mutational burden (TMB), microsatellite instability (MSI), T cell-inflamed microenvironment, and TGFβ expression profile are candidate biomarkers for CRC, but their analyses are expensive, delayed, and not easily available (56, 57). This evidence concerns the gene TGFB1 and colorectal carcinoma.